Evidence map›Paper›PMID 35509981›Full record

ArticleJournal of immunology research2022

A Comprehensive Prognostic and Immune Analysis of Ferroptosis-Related Genes Identifies SLC7A11 as a Novel Prognostic Biomarker in Lung Adenocarcinoma.

Li Qian, Fu Wang, Shu-Min Lu, Hua-Jie Miao, Xin He, Jia Feng, Hua Huang, Rong-Feng Shi, Jian-Guo Zhang

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Genetic profile of ferroptosis in non-small cell lung carcinoma and pharmaceutical options for ferroptosis induction.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Li QianDepartment of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Fu WangDepartment of Traditional Chinese Medicine, Nantong Maternity and Child Health Care Hospital Affiliated to Nantong University, Nantong, Jiangsu, China.
Shu-Min LuDepartment of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hua-Jie MiaoDepartment of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Xin HeDepartment of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Jia FengDepartment of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Hua HuangDepartment of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Rong-Feng ShiDepartment of Interventional Radiology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.ORCID https://orcid.org/0000-0001-6686-7342
Jian-Guo ZhangDepartment of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.ORCID https://orcid.org/0000-0002-6984-8523
Nantong University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is still one of the illnesses with the greatest mortality and morbidity. As a recently identified mode of cellular death, the activation of ferroptosis may promote the effectiveness of antitumor therapies in several types of tumors. However, the expression and clinical significance of Ferroptosis-associated genes in LUAD are still elusive. The RNA sequencing data of LUAD and relevant clinical data were downloaded from The Cancer Genome Atlas (TCGA) datasets. Subsequently, potential prognostic biomarkers were determined by the use of biological information technology. The R software package "ggalluvial" was applied to structure Sanguini diagram. Herein, our team screened 14 dysregulated ferroptosis-associated genes in LUAD. Among them, only four genes were associated with clinical outcome of LUAD patients, including ATP5MC3, FANCD2, GLS2, and SLC7A11. In addition, we found that high SLC7A11 expression predicted an advanced clinical progression in LUAD patients. Additionally, 8 immune checkpoint genes and 7 immune cells for LUAD were recognized to be related to the expression of SLC7A11. KEGG assays indicated that high expression of SLC7A11 might participate in the modulation of intestinal immune network for IgA generation and Staphylococcus aureus infection. Overall, our findings revealed that SLC7A11 might become a potentially diagnostic biomarker and SLC7A11 might serve as an independent prognosis indicator for LUAD.

Indexed as

Adenocarcinoma of LungFerroptosisLung NeoplasmsAmino Acid Transport System y+BiomarkersHumansPrognosisAmino Acid Transport System y+BiomarkersSLC7A11 protein, human

Identifiers

PMID35509981
PMCPMC9061045
OpenAlexW4224444534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.